GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (LTS:0A8E) » Definitions » Short-Term Capital Lease Obligation

Xeris Biopharma Holdings (LTS:0A8E) Short-Term Capital Lease Obligation : $4.6 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Xeris Biopharma Holdings Short-Term Capital Lease Obligation?

Xeris Biopharma Holdings's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $4.6 Mil.

Xeris Biopharma Holdings's quarterly Short-Term Capital Lease Obligation increased from Sep. 2023 ($2.4 Mil) to Dec. 2023 ($3.5 Mil) and increased from Dec. 2023 ($3.5 Mil) to Mar. 2024 ($4.6 Mil).

Xeris Biopharma Holdings's annual Short-Term Capital Lease Obligation increased from Dec. 2021 ($0.0 Mil) to Dec. 2022 ($1.6 Mil) and increased from Dec. 2022 ($1.6 Mil) to Dec. 2023 ($3.5 Mil).


Xeris Biopharma Holdings Short-Term Capital Lease Obligation Historical Data

The historical data trend for Xeris Biopharma Holdings's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Short-Term Capital Lease Obligation Chart

Xeris Biopharma Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Capital Lease Obligation
Get a 7-Day Free Trial - - - 1.58 3.50

Xeris Biopharma Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Short-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.45 1.94 2.37 3.50 4.62

Xeris Biopharma Holdings Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.


Xeris Biopharma Holdings Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Xeris Biopharma Holdings (LTS:0A8E) Business Description

Traded in Other Exchanges
Address
180 North LaSalle Street, Suite 1600, Chicago, IL, USA, 60601
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.

Xeris Biopharma Holdings (LTS:0A8E) Headlines

No Headlines